Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccines with Peptide-pulsing or mRNA Transfection in Melanoma
NCT00243529Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2004
- Primary completion
- Feb 2009
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous dendritic cell vaccine in melanoma (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Immune response at 10 years. Started Apr 2004; status: completed.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00243529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243529.